Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Izaflortaucipir (18F) in Alzheimer Disease: NCT05456503 Clinical Landscape Report 2026
16 October 2026
NCT05456503 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Retreatment Rhenium Liposome in Recurrent Glioma: NCT05460507 Clinical Landscape Report 2026
16 October 2026
NCT05460507 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
B7-H3CART(Stanford University) in Glioblastoma Multiforme: NCT05474378 Clinical Landscape Report 2026
16 October 2026
NCT05474378 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efineptakin alfa (Genexine) in Gliosarcoma: NCT05465954 Clinical Landscape Report 2026
16 October 2026
NCT05465954 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Glioblastoma: NCT05502991 Clinical Landscape Report 2026
16 October 2026
NCT05502991 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PhOx-430 in Glioblastoma Multiforme: NCT05495295 Clinical Landscape Report 2026
16 October 2026
NCT05495295 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VRG-50635 in Amyotrophic Lateral Sclerosis: NL-OMON56052 Clinical Landscape Report 2026
16 October 2026
NL-OMON56052 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Riluzole in Amyotrophic Lateral Sclerosis: NCT05508074 Clinical Landscape Report 2026
16 October 2026
NCT05508074 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gallium-68 P16-093 in Glioblastoma: NCT05569434 Clinical Landscape Report 2026
16 October 2026
NCT05569434 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LuCaFab in Glioblastoma Multiforme: NCT05533242 Clinical Landscape Report 2026
16 October 2026
NCT05533242 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Recurrent Glioblastoma: NCT05540275 Clinical Landscape Report 2026
16 October 2026
NCT05540275 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PRT-3645 in Sarcoma: NCT05538572 Clinical Landscape Report 2026
16 October 2026
NCT05538572 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.